GSK reports mixed findings from ovarian cancer phase III study
20th Dec 2024 08:58
(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. Read More
| Price | 1,320.00p on 20-12-2024 at 18:50:41 |
|---|---|
| Change | -2.00p -0.15% |
| Buy | 1,323.00p |
| Sell | 1,322.00p |
| Buy / Sell GSK Shares | |
| Last Trade: | Unknown 0.00 at 1,315.00p |
| Day's Volume: | 13,999,806 |
| Last Close: | 1,320.00p |
| Open: | 1,308.50p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,302.50p - 1,323.50p |
| 52wk Range: | 1,282.50p - 1,820.00p |
| Market Capitalisation: | £53,863m |
| VWAP: | 1,316.61326p |
| Shares in Issue: | 4,081m |
Recent Trades History Glaxosmithkline (GSK) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 1,315.00p | OTC Trade |
15:04:55 - 20-Dec-24 |
| Unknown* | 0 | 1,314.50p | OTC Trade |
15:03:13 - 20-Dec-24 |
| Unknown* | 1 | 1,313.50p | OTC Trade |
15:00:54 - 20-Dec-24 |
| Unknown* | 20 | 1,309.50p | OTC Trade |
14:51:41 - 20-Dec-24 |
| Unknown* | 1 | 1,309.50p | OTC Trade |
14:51:41 - 20-Dec-24 |
| Unknown* | 339,345 | 1,308.50p | OTC Trade |
17:24:55 - 20-Dec-24 |
| Unknown* | 339,345 | 1,308.50p | OTC Trade |
17:24:53 - 20-Dec-24 |
| Unknown* | 0 | 1,309.50p | OTC Trade |
14:48:47 - 20-Dec-24 |
| Unknown* | 0 | 1,310.00p | OTC Trade |
14:46:49 - 20-Dec-24 |
| Unknown* | 5 | 1,309.50p | OTC Trade |
14:48:27 - 20-Dec-24 |